The U.S. Supreme Court temporarily reinstated online access to the abortion pill mifepristone by mail, pausing a federal appeals court ruling that had blocked prescribing by phone and through the mail. The stay runs through May 11 while the court considers further action. Manufacturers Danco and GenBioPro sought emergency relief, arguing the appeals court order created regulatory chaos and disrupted orderly administration of the drug. The decision also allows patients with existing appointments to avoid treatment interruptions. The lower-court action stemmed from a lawsuit filed by Louisiana seeking reinstatement of an FDA in-person consultation requirement. Federal availability of telemedicine for mifepristone was lifted in 2021 during the COVID-19 pandemic.